Since the dependency of clinicopathologic data and BRAF V600E mutation in ameloblastomas remains questionable and conflicting, further studies are required in future to explain the real relationship of this mutation with the aggressiveness of ameloblastoma. The gene discussed is BRAF; the disease is ameloblastoma.